Compliance Policy Guide Sec. 400.400 Conditions Under Which Homeopathic Drugs May Be Marketed; Withdrawal of Guidance, 57439-57441 [2019-23334]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 84, Number 207 (Friday, October 25, 2019)]
[Notices]
[Pages 57439-57441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-23334]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-4611]


Compliance Policy Guide Sec. 400.400 Conditions Under Which 
Homeopathic Drugs May Be Marketed; Withdrawal of Guidance

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; withdrawal.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the withdrawal of Compliance Policy Guide Sec. 400.400 (CPG 400.400) 
entitled ``Conditions Under Which Homeopathic Drugs May be Marketed,'' 
which was issued in 1988.

DATES: The withdrawal is applicable October 25, 2019.

FOR FURTHER INFORMATION CONTACT: Elaine Lippmann, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6238, Silver Spring, MD 20993, 301-796-
3600.

[[Page 57440]]


SUPPLEMENTARY INFORMATION: FDA is withdrawing CPG 400.400, entitled 
``Conditions Under Which Homeopathic Drugs May be Marketed,'' which was 
issued in 1988. CPG 400.400 described an enforcement policy regarding 
homeopathic drug products.
    Under section 505(a) of the Federal Food, Drug, and Cosmetic Act 
(FD&C Act) (21 U.S.C. 355(a)), before any ``new drug'' is marketed, it 
must be the subject of an approved application filed pursuant to 
section 505(b) or section 505(j) of the FD&C Act. The requirements in 
section 505 of the FD&C Act apply to biological products regulated 
under section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 
262); however, as stated in section 351(j) of the PHS Act, a biological 
product with an approved license under section 351(a) of the PHS Act is 
not required to have an approved application under section 505 of the 
FD&C Act. Accordingly, absent a determination that a homeopathic drug 
product is not a ``new drug'' under section 201(p) of the FD&C Act (21 
U.S.C. 321(p)), all homeopathic drug products are subject to the 
premarket approval requirements in section 505 of the FD&C Act or 
section 351 of the PHS Act. There are currently no homeopathic drug 
products approved by FDA.
    Since the issuance of CPG 400.400, the Agency has encountered 
multiple situations in which homeopathic drug products posed a 
significant risk to patients. There is a broad misconception that all 
homeopathic products are highly diluted and generally composed of 
``natural'' ingredients, and that they are therefore incapable of 
causing harm. However, as with all drugs, the safety of homeopathic 
drugs depends upon many factors, such as the product's intended use, 
dosage form, frequency of use, manufacturing quality, intended patient 
population, and the quantity and combination of ingredients. CPG 
400.400 does not directly address all these important considerations.
    For example, FDA has encountered situations in which homeopathic 
products either caused or could have caused significant harm, even 
though the products, as labeled, appeared to meet the conditions 
described in CPG 400.400. In 2016, FDA's search of the FDA Adverse 
Event Reporting System database identified 99 cases of adverse events 
consistent with belladonna toxicity, including reports of infant deaths 
and seizures, possibly related to teething products. Multiple 
homeopathic drug products were identified as associated with this 
safety concern. Further investigation revealed that the poisonous 
belladonna alkaloids in some of the products far exceeded the labeled 
amounts, raising a serious safety concern. As another example, by 2009, 
FDA had received more than 130 reports of anosmia (loss of the sense of 
smell) associated with the use of Zicam homeopathic intranasal zinc 
products. FDA determined that if the products were used as labeled, a 
user would receive significant daily intranasal exposure to zinc, 
raising a serious safety concern. These are only two examples among 
many. FDA has also, for example, documented many serious violations of 
current good manufacturing practice (CGMP) requirements by 
manufacturers of homeopathic drug products, raising significant 
concerns about the safety of the products made with inadequate process 
controls.
    The homeopathic drug industry has grown significantly since FDA 
issued CPG 400.400 in 1988. According to the National Health Interview 
Survey, conducted by the Centers for Disease Control and Prevention's 
National Center for Health Statistics, between 2007 and 2012 the use of 
homeopathic products increased by approximately 15 percent in U.S. 
adults. This growth, and the increased population exposure that it 
apparently represents, has contributed to FDA's enhanced focus on the 
safety of homeopathic drugs in recent years and the evaluation of the 
CPG, which was issued over three decades ago.
    In light of the growth of the industry and passage of time since 
the issuance of CPG 400.400, FDA announced on March 27, 2015, that it 
was evaluating its regulatory framework for homeopathic drug products. 
In April 2015, FDA held a public hearing to obtain information and 
comments from stakeholders about the current use of homeopathic drug 
products, as well as the Agency's regulatory framework for such 
products (Docket No. FDA-2015-N-0540; available at https://www.regulations.gov/docket?D=FDA-2015-N-0540). FDA sought broad public 
input on its enforcement policies related to homeopathic drug products 
to better promote and protect the public health. On December 18, 2017, 
FDA issued a draft guidance entitled ``Drug Products Labeled as 
Homeopathic; Guidance for FDA Staff and Industry.'' The draft guidance 
detailed a risk-based enforcement policy, prioritizing enforcement and 
regulatory actions for certain categories of homeopathic products that 
potentially pose higher risk to public health.
    In response to comments received, we have revised the draft 
guidance and are announcing the reissue of it elsewhere in this issue 
of the Federal Register to enable the public to review and comment 
before it is finalized. In particular, we have added a definition of 
``homeopathic drug product'' for purposes of the guidance, added an 
additional explanation of some of the safety issues that contributed to 
the development of the draft guidance, and clarified the intent to use 
risk-based factors to prioritize enforcement and regulatory actions 
involving homeopathic products that are marketed without required FDA 
approval. In addition, the revised draft guidance removes the statement 
that the Agency will withdraw the CPG simultaneous with the issuance of 
the final guidance.
    As a result of the Agency's ongoing evaluation of its regulatory 
framework, including consideration of the public input received on this 
issue and the recent growth of safety concerns associated with 
homeopathic drug products, FDA believes that it is appropriate to 
withdraw CPG 400.400 at this time, rather than waiting for the issuance 
of the final guidance. Because CPG 400.400 is inconsistent with the 
Agency's risk-based approach to enforcement generally, it does not 
accurately reflect the Agency's current thinking. When the draft 
guidance is finalized, it will specify the categories of products that 
the Agency intends to prioritize for enforcement. In the interim, 
before the draft guidance is finalized, FDA intends to apply its 
general approach to prioritizing regulatory and enforcement action, 
which involves risk-based prioritization in light of all the facts of a 
given circumstance. Risk-based enforcement best reflects FDA's public 
health priorities.
    We note that withdrawing the CPG does not represent a change in the 
legal obligations that apply to homeopathic drugs under the statutes 
FDA administers. The definition of a ``drug'' under section 
201(g)(1)(A) through (C) of the FD&C Act includes: (1) Articles 
recognized in the official United States Pharmacopoeia or the official 
Homoeopathic Pharmacopoeia of the United States; (2) articles intended 
for use in the diagnosis, cure, mitigation, treatment, or prevention of 
disease in man or other animals; and (3) articles (other than food) 
intended to affect the structure or any function of the body of man or 
other animals. As such, homeopathic drugs are subject to the same 
regulatory requirements as other drugs; nothing in the FD&C Act exempts 
homeopathic drug products from any of the requirements in the FD&C Act, 
including those related to approval, adulteration, and misbranding.

[[Page 57441]]

    Generally, a drug, including a homeopathic drug, is considered a 
``new drug'' if it is not generally recognized as safe and effective by 
qualified experts for use under the conditions prescribed, recommended, 
or suggested in the labeling (section 201(p) of the FD&C Act). CPG 
400.400 did not, and legally could not, provide a path for legal 
marketing of unapproved new drugs, including those that are 
homeopathic. Rather, the CPG merely described an enforcement policy 
regarding homeopathic drug products. The Agency does not have authority 
to exempt a product or class of products that are new drugs under the 
FD&C Act from the new drug approval requirements of the FD&C Act. (See 
Cutler v. Kennedy, 475 F. Supp. 838, 856 (D.D.C. 1979); Hoffman-LaRoche 
v. Weinberger, 425 F. Supp. 890, 892-894 (D.D.C. 1975). See also Util. 
Air Regulatory Grp. v. EPA, 573 U.S. 302, 327 (2014) (``An agency 
confronting resource constraints may change its own conduct, but it 
cannot change the law.'')).
    The Agency's interest in its general risk-based enforcement 
approach also justifies withdrawing an outdated policy that does not 
reflect that approach. Additionally, withdrawal of the CPG is 
appropriate given the recent growth of safety concerns associated with 
homeopathic drug products--including concerns regarding products 
associated with serious adverse events and otherwise presenting 
significant safety risks and serious violations of CGMP requirements--
and the increasing number of consumer exposures due to the continued 
expansion of the homeopathic industry since issuance of the CPG.

    Dated: October 22, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-23334 Filed 10-24-19; 8:45 am]
BILLING CODE 4164-01-P